Literature DB >> 21853302

Interleukin 6 mediates production of interleukin 10 in metastatic melanoma.

Mizue Terai1,2,3, Masumi Eto4, Garbo D Young4, David Berd5, Michael J Mastrangelo2, Yutaka Tamura3, Kenichi Harigaya1, Takami Sato6,7.   

Abstract

We previously reported that substantial amounts of IL-10, an immunomodulatory cytokine, are produced by cell suspensions of fresh human metastatic melanoma tissues. Production diminished with continuous culturing of cells, which suggests a pivotal interactive role between melanoma cells and the tumor microenvironment. In this study, we found that the culture media obtained from LPS-stimulated peripheral blood mononuclear cells induced IL-10 production by metastatic melanoma cells. Of the multiple cytokines present in the conditioned culture media, IL-6 was identified as the inducer of IL-10 production. A neutralizing antibody against IL-6 completely blocked the conditioned medium-induced IL-10 production. Metastatic melanoma cells that constitutively produce low amount of IL-10 increased IL-10 production in response to recombinant human IL-6 in a dose-dependent fashion. The response to exogenously added IL-6 was less significant in melanoma cells that produced high amounts of IL-6, probably due to pre-existing autocrine stimulation of IL-10 by endogenous IL-6. On the other hand, metastatic melanoma cells that do not constitutively produce IL-10 protein did not respond to exogenous IL-6. In IL-6-responsive melanoma cells, IL-6 increased STAT3 phosphorylation and inhibition of STAT3 signaling using siRNA or inhibitors for JAKs diminished IL-6-induced IL-10 production. In addition, inhibition of MEK and PI3K, but not mTOR, interfered with IL-10 production. Taken together, the data suggest that blocking of these signals leading to IL-10 production is a potential strategy to enhance an anti-melanoma immune response in metastatic melanoma.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21853302     DOI: 10.1007/s00262-011-1084-5

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  18 in total

Review 1.  Interleukin 10 in the tumor microenvironment: a target for anticancer immunotherapy.

Authors:  Takami Sato; Mizue Terai; Yutaka Tamura; Vitali Alexeev; Michael J Mastrangelo; Senthamil R Selvan
Journal:  Immunol Res       Date:  2011-12       Impact factor: 2.829

2.  F-actin clustering and cell dysmotility induced by the pathological W148R missense mutation of filamin B at the actin-binding domain.

Authors:  Yongtong Zhao; Sandor S Shapiro; Masumi Eto
Journal:  Am J Physiol Cell Physiol       Date:  2015-10-21       Impact factor: 4.249

3.  Intensive cytokine induction in pandemic H1N1 influenza virus infection accompanied by robust production of IL-10 and IL-6.

Authors:  Xuelian Yu; Xi Zhang; Baihui Zhao; Jiayu Wang; Zhaokui Zhu; Zheng Teng; Junjie Shao; Jiaren Shen; Ye Gao; Zhengan Yuan; Fan Wu
Journal:  PLoS One       Date:  2011-12-09       Impact factor: 3.240

Review 4.  Perspective of Targeting Cancer-Associated Fibroblasts in Melanoma.

Authors:  Linli Zhou; Kun Yang; Thomas Andl; R Randall Wickett; Yuhang Zhang
Journal:  J Cancer       Date:  2015-06-23       Impact factor: 4.207

5.  miR-98 suppresses melanoma metastasis through a negative feedback loop with its target gene IL-6.

Authors:  Fei Li; Xin-ji Li; Li Qiao; Fei Shi; Wen Liu; You Li; Yu-ping Dang; Wei-jie Gu; Xiao-gang Wang; Wei Liu
Journal:  Exp Mol Med       Date:  2014-10-03       Impact factor: 8.718

6.  Immunological monitoring for prediction of clinical response to antitumor vaccine therapy.

Authors:  Irina N Mikhaylova; Irina Zh Shubina; George Z Chkadua; Natalia N Petenko; Lidia F Morozova; Olga S Burova; Robert Sh Beabelashvili; Kermen A Parsunkova; Natalia V Balatskaya; Dmitrii K Chebanov; Vadim I Pospelov; Valeria V Nazarova; Anastasia S Vihrova; Evgeny A Cheremushkin; Alvina A Molodyk; Mikhail V Kiselevsky; Lev V Demidov
Journal:  Oncotarget       Date:  2018-05-11

Review 7.  Influence of Tumor Microenvironment and Fibroblast Population Plasticity on Melanoma Growth, Therapy Resistance and Immunoescape.

Authors:  Veronica Romano; Immacolata Belviso; Alessandro Venuta; Maria Rosaria Ruocco; Stefania Masone; Federica Aliotta; Giuseppe Fiume; Stefania Montagnani; Angelica Avagliano; Alessandro Arcucci
Journal:  Int J Mol Sci       Date:  2021-05-17       Impact factor: 5.923

8.  The immunomodulatory effects of bevacizumab on systemic immunity in patients with metastatic melanoma.

Authors:  Aaron S Mansfield; Wendy K Nevala; Elizabeth Ann T Lieser; Alexey A Leontovich; Svetomir N Markovic
Journal:  Oncoimmunology       Date:  2013-05-01       Impact factor: 8.110

9.  Tumour hypoxia promotes melanoma growth and metastasis via High Mobility Group Box-1 and M2-like macrophages.

Authors:  Roman Huber; Barbara Meier; Atsushi Otsuka; Gabriele Fenini; Takashi Satoh; Samuel Gehrke; Daniel Widmer; Mitchell P Levesque; Joanna Mangana; Katrin Kerl; Christoffer Gebhardt; Hiroko Fujii; Chisa Nakashima; Yumi Nonomura; Kenji Kabashima; Reinhard Dummer; Emmanuel Contassot; Lars E French
Journal:  Sci Rep       Date:  2016-07-18       Impact factor: 4.379

10.  Demonstration of a WNT5A-IL-6 positive feedback loop in melanoma cells: Dual interference of this loop more effectively impairs melanoma cell invasion.

Authors:  Rickard Linnskog; Purusottam Mohapatra; Farnaz Moradi; Chandra Prakash Prasad; Tommy Andersson
Journal:  Oncotarget       Date:  2016-06-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.